Conopeptide-Derived κ‑Opioid Agonists (Conorphins): Potent, Selective, and Metabolic Stable Dynorphin A Mimetics with Antinociceptive Properties by Brust, Andreas et al.
Conopeptide-Derived κ‑Opioid Agonists (Conorphins): Potent,
Selective, and Metabolic Stable Dynorphin A Mimetics with
Antinociceptive Properties
Andreas Brust,*,†,‡ Daniel E. Croker,†,‡ Barbara Colless,†,‡ Lotten Ragnarsson,†,‡ Åsa Andersson,†,‡
Kapil Jain,‡ Sonia Garcia-Caraballo,§ Joel Castro,§ Stuart M Brierley,§ Paul F. Alewood,‡
and Richard J. Lewis*,†,‡
†Xenome Limited, Brisbane, Queensland 4068, Australia
‡Institute for Molecular Biosciences, The University of Queensland, Brisbane, Queensland, 4072, Australia
§Visceral Pain Group, Centre for Nutrition and Gastrointestinal Disease, Discipline of Medicine, The University of Adelaide, South
Australian Health and Medical Research Institute, SAHMRI, Adelaide, SA 5000, Australia
*S Supporting Information
ABSTRACT: Opioid receptor screening of a conopeptide library led to a novel selective κ-opioid agonist peptide (conorphin
T). Intensive medicinal chemistry, guided by potency, selectivity, and stability assays generated a pharmacophore model
supporting rational design of highly potent and selective κ-opioid receptor (KOR) agonists (conorphins) with exceptional plasma
stability. Conorphins are defined by a hydrophobic benzoprolyl moiety, a double arginine sequence, a spacer amino acid followed
by a hydrophobic residue and a C-terminal vicinal disulfide moiety. The pharmacophore model was supported by computational
docking studies, revealing receptor−ligand interactions similar to KOR agonist dynorphin A (1−8). A conorphin agonist
inhibited colonic nociceptors in a mouse tissue model of chronic visceral hypersensitivity, suggesting the potential of KOR
agonists for the treatment of chronic abdominal pain. This new conorphine KOR agonist class and pharmacophore model
provide opportunities for future rational drug development and probes for exploring the role of the κ-opioid receptor.
■ INTRODUCTION
Marine natural products remain an important source of new
chemical diversity for drug discovery.1,2 Venoms from the
genus Conus (marine cone snails) provide an enriched source of
highly evolved bioactive compounds.3 These predatory
molluscs are equipped with a venom apparatus that produces
a species-specific cocktail of peptides to immobilize prey that
comprise fish, molluscs, or worms. It is estimated that the
venom of a single Conus species typically contain in excess of
1000 unique venom peptides called conotoxins or conopeptides
which translates to >500 000 potentially bioactive peptides
across the genus.3−5 Conotoxins are highly specific for
membrane protein targets and usually possess constrained
structures with multiple disulfide bonds.3 The disulfide bond
framework is interspersed by loops of amino acids that typically
contain the binding residues presented in a well-defined three-
dimensional space. The potency, selectivity, and chemical
stability of conotoxins make these compounds attractive
starting points for drug development.6−11 In fact, several
conotoxins are currently in clinical trials, with ω-conotoxin
MVIIA (ziconotide)12,13 on the market for the treatment of
chronic pain.12,13 On the basis of their untapped pharmacolgical
potential,14−18 we developed a synthetic conopeptide library19
comprising >2000 peptides, from nucleotide derived venom
peptide sequences to be used as a platform for novel drug lead
discovery.
Opioid receptors are a major target for pain manage-
ment.20−24 Three opioid receptors have been cloned: the μ-
(MOR), κ- (KOR), and δ- (DOR) opioid receptor.25,26 In
addition, the nociceptin/orphanin FQ receptor (NOP) is an
“opioid-related” receptor that exhibits a high degree of
structural homology to conventional opioid receptors despite
having distinct pharmacology.27,28 KOR is different from the
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other opioid receptors in terms of tissue expression patterns,
functional properties, and side effect profile upon activation.29
Morphine and related opiates are to date the most potent
analgesics and predominantly modulate MOR expressed in the
central nervous system. However, the effects at MOR expressed
in the periphery contribute also to serious dose-limiting side
effects.30,31 In contrast to this, modulation of KOR in the CNS
results in side effects such as hallucinations and disphoria.29,32
Development of peripherally restricted selective ligands for
the KOR is of considerable therapeutic interest as potential
analgesic.29,32,33 In general KOR agonists are of interest for a
variety of other therapeutic applications. KOR agonists produce
analgesia without MOR agonist related side effects; in addition
to their anti-inflammatory34 and neuroprotective effects, they
suppress the rewarding effects of opiates and cocaine.35,36 KOR
agonists also are potential therapeutics for pruritus,37
depression,38,39 opiate dependence,36 and cocaine seeking
behavior.35,40 In particular KOR agonists have been shown to
exert analgesic activity in a variety of visceral pain models
mediated by peripherally expressed KOR, suggesting that a
peripherally restricted KOR agonist might be useful treatment
for a variety of visceral pain conditions, including postoperative
pain, ileus, pancreatitis pain, dysmenorrhea, labor pain, and
functional bowel disorders.32,34,40,41 One such KOR agonist,
asimadoline (N-[(1S)-2-[(3S)-3-hydroxypyrrolidin-1-yl]-1-phe-
nylethyl]-N-methyl-2,2-diphenylacetamide),42 appears to inhib-
it nociception via activation of KORs expressed on the
peripheral endings of colonic nociceptors,43 suggesting a
peripherally restricted KOR agonist might be useful treatment
for a variety of visceral pain conditions including irritable bowel
syndrome (IBS).
Dynorphin A (YGGFLRRIRPKLKWDNQ or dynA (1−17))
is the endogenous agonist of human KOR. DynA (1−17)
contains the N-terminal YGGF message sequence common to
endogenous opioids, like endorphins and enkephalins, which
contributes to opiate receptor affinity but not opiate receptor
selectivity.44 Removal of as many as nine residues from the C-
terminus of dynA (1−17) has little effect on KOR activity.45,46
In addition replacement of the nine C-terminal residues of
dynA (1−17) with those of nociceptin also maintained activity
at KOR.47 From this it can be concluded that the essential
pharmacophore of dynA (1−17) lies within the N-terminal
fragment dynA (1−8) (YGGFLRRI). Docking simulations of
dynA (1−8) binding to the KOR revealed a partially stabilized
α-helix from Phe4 to Ile8, allowing the YGGF message domain
to bind in a hydrophobic binding pocket comprising elements
from transmembrane helices 3, 5, 6, and 7 of KOR.48 The
recent X-ray structure of KOR in complex with an antagonist
(JDTic; (3R)-7-hydroxy-N-[(2S)-1-[(3R,4R)-4-(3-hydroxy-
phenyl)-3,4-dimethylpiperidin-1-yl]-3-methylbutan-2-yl]-
1,2,3,4-tetrahydroisoquinoline-3-carboxamide)49 has been used
to confirm earlier docking results and is supported by receptor
mutagenesis and functional studies.50 The consensus view is
that the YGGF message domain interacts with KOR in a similar
way as the antagonist JDTic, encompassing a conserved opioid
receptor hydrophobic pocket comprising W124(ECL1),
V134(3.28), I135(3.19), and C210(ECL2). Additionally the
D138(3.32) carboxylate interaction with the Y1-amine residue
is also critical for high affinity interactions.49 The dynA (1−8)
KOR address domain LRRI presented in an extended
conformation with multiple KOR interactions, with a
Q115(2.60) to NH interaction at Leu5 of particular impor-
tance.50 A prominent salt bridge between E297(6.58) and Arg7
residues in the address sequence of dynA (1−8) was also
identified that likely contributes strongly to KOR receptor
selectivity.49,50
Previous small molecule KOR agonist molecules (e.g.,
fedotozine, (2R)-N,N-dimethyl-2-phenyl-1-[(3,4,5-trimethoxy-
benzyl)oxy]-2-butanamine)51 have failed in clinical develop-
ment51 due to limited selectivity/potency or significant blood−
brain barrier penetration which led to unwanted central side
effects.51 However, the peripherally restricted KOR agonist
asimadoline42,52 is currently in phase 3 clinical trials for the
treatment of pain associated with irritable bowel syndrome.42,43
Peripherally restricted KOR agonists have been developed
based on peptidic molecules53,54 by CARA Therapeutics [D-
Phe-D-Phe-D-Nle-D-Arg-NH-4-picolyl (CR665) and D-Phe-D-
Phe-D-Leu-D-Lys-[γ-(4-N-piperidinyl)aminocarboxylic acid
(CR845)]53,54 which combine high affinity, excellent selectivity,
and limited or no central side effects and are currently
undergoing phase 2 testing for postoperative pain.53,54
In the present study, a KOR agonist (1) named conorphin-T
(sequence: NCCRRQICC) was identified from the screening
of a Conus venom peptide library across the opiate receptors.
Detailed structure−activity studies and medicinal chemistry
optimization generated a new class of metabolically stable lead
molecules that had subnanomolar affinity and high selectivity
for KOR over the other opioid receptors. Here we describe the
development and visceral analgesic efficacy of potent KOR
agonist conorphins and the associated pharmacophore model
that describes their binding to KOR.
■ RESULTS AND DISCUSSION
Library Screening and Initial Hit Identification. A
synthetic peptide library containing over 2000 conopeptides
from cDNA libraries obtained from venom duct preparations of
cone shells was screened in a binding assay across a panel of
human KOR, MOR, and DOR receptors. This screen revealed a
previously uncharacterized nine amino acid peptide 1 we name
conorphin-T, whose sequence was previously found in a cDNA
library from C. textile.55 1 contains two disulfide bonds and was
identified as a KOR agonist, without detectable binding at the
other opioid receptors (Table 3).
By use of selective disulfide bond formation, the affinity of
each individual disulfide isomer was assessed at KOR by
radioligand binding assay. Peptide 1 in the bead form (1−2, 3−
4 disulfide connectivity) (Figure 1, Table 1) was identified as
the most active isomer at KOR, and its structure−activity was
investigated to uncover more potent analogues suitable for
further development. Selected synthetic analogues were
Figure 1. KOR affinity of 1 and its disulfide isomers. Data shown are
the mean ± SEM values of at least three independent experiments
each performed in triplicate.
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Table 1. Activity and Stability of Dynorphin, the Venom Library Conorphine (1), and Its Analogues 2−75a
compd sequence Ki ± SD (nM) ERK EC50 ± SD (nM) cAMP EC50 ± SD (nM) T1/2 plasma
dynorphin A (1−17) YGGFLRRIRPKLKWDNQ-NH2 0.28 ± 0.25 0.95 ± 0.34 1.2 ± 0.24 120 min
dynorphin A (1−13) YGGFLRRIRPKLK-NH2 0.40 ± 0.72
1 (1−3, 2−4) NCCRRQICC-NH2 1474 ± 1965
1 (1−4, 2−3) NCCRRQICC-NH2 580 ± 277
1 (1−2, 3−4) NCCRRQICC-NH2 80.4 ± 42.6 9848 ± 3272 9446 ± 403 15 min
2 NCCARQICC-NH2 170 ± 68
3 NCCRAQICC-NH2 406 ± 242
4 NCCRRAICC-NH2 133 ± 74
5 NCCRRQACC-NH2 2452 ± 515
6 UCCRRQICC-NH2 67.5 ± 6.7 5864 ± 3259 11.5 ± 1.7 15 min
7 YCCRRQICC-NH2 40.3 ± 8.2
8 RRQI-NH2 23003 ± 9232
9 NCCRRQI-NH2 14662 ± 1542
10 RRQICC-NH2 270 ± 61 45 min
11 URRQICC-NH2 191 ± 35 7486 ± 1701 1.9 ± 1.7 180 min
12 NCCRRQVCC-NH2 664 ± 424
13 NCCRRQLCC-NH2 24.8 ± 3.9
14 NCCRRQ[CHA]CC-NH2 1.3 ± 1.1 <15 min
15 NCCRRQFCC-NH2 28.4 ± 8.1
16 NCCRRQ[NAL]CC-NH2 2.9 ± 0.8 <15 min
17 NCCHRQICC-NH2 137 ± 79
18 NCCRHQICC-NH2 85 ± 75.5
19 NCCKRQICC-NH2 426.9 ± 381
20 NCCRKQICC-NH2 208 ± 193
21 NCC[CIT]RQICC-NH2 218 ± 18
22 NCCR[CIT]QICC-NH2 387 ± 127
23 URRQ[CHA]CC-NH2 6.7 ± 1.1 1580 ± 439 15.2 ± 7.4 90 min
24 UrRQ[CHA]CC-NH2 13 ± 5.3 90 min
25 URrQ[CHA]CC-NH2 16.1 ± 9.3 1200 min
26 UrrQ[CHA]CC-NH2 3.9 ± 1.5 1105 ± 839 12.6 ± 3.6 360 min
27 4F-Bz-rrQ[CHA]CC-NH2 5.4 ± 1.7
28 3Br-Bz-rrQ[CHA]CC-NH2 5.3 ± 0.8
29 3Cl-Bz-rrQ[CHA]CC-NH2 6.7 ± 1.4
30 4F-Bnz-rrQ[CHA]CC-NH2 1.2 ± 0.3
31 3Br-Bnz-rrQ[CHA]CC-NH2 1.2 ± 0.7
32 3Cl-Bnz-rrQ[CHA]CC-NH2 2.1 ± 0.8
33 [Anc]rrQ[CHA]CC-NH2 0.64 ± 0.24 60 min
34 3-Qin-rrQ[CHA]CC-NH2 0.71 ± 0.42 45 min
35 [TIC]rrQ[CHA]CC-NH2 0.91 ± 0.35 45 min
36 [TIQ]rrQ[CHA]CC-NH2 1.18 ± 0.36 45 min
37 Nz-PrrQ[CHA]CC-NH2 0.07 ± 0.02 30 min
38 4Cl-Bz-PrrQ[CHA]CC-NH2 0.13 ± 0.03 60 min
39 Bz-PrrQ[CHA]CC-NH2 0.25 ± 0.13 0.36 ± 0.11 0.41 ± 0.11 240 min
40 4MeO-Bz-PrrQC[CHA]CC-NH2 0.59 ± 0.14 120 min
41 3,4Cl-Bz-PrrQC[CHA]CC-NH2 0.98 ± 0.2 60 min
42 4HO-Bz-PrrQC[CHA]CC-NH2 1.2 ± 0.3 120 min
43 4-NO2−Bz-PrrQC[CHA]CC-NH2 2.2 ± 0.5
44 UrrQ[CHA][PEN]C-NH2 1.3 ± 0.5 450 ± 198 10.5 ± 3.2 100% at 24 h
45 Bz-PrrQ[CHA][PEN]C-NH2 1140 ± 891 95% at 24 h
46 Bz-PrrQ[CHA][NMC]C-NH2 15.2 ± 8.8
47 Bz-PrrQ[CHA]-CH2-NH-CC-NH2 135 ± 32 960 min
48 Bz-PrrQ[CHG]CC-NH2 0.48 ± 0.22 0.62 ± 0.31 0.39 ± 0.23 1200 min
49 UrrQ[CHA][HCY]C-NH2 783 ± 133
50 UrrQ[CHA]C[HCY] -NH2 1573 ± 822
51 UrrQ[CHA][HCY][HCY] -NH2 241 ± 31
52 [TIC]rrQ[CHA][SEC][SEC] -NH2 2.4 ± 0.3 360 min
53 UrrQ[CHA][SEC]C-NH2 7.8 ± 1.7 360 min
54 Bz-PrrQ[CHA](D[DAP]) -NH2 233 ± 90
55 Bz-PrrQ[CHA]CC CH2-NH2 bridge 15.8 ± 9.7
56 Bz-PrrQ{CHA]C[MEG] -NH2 465 ± 311
57 Bz-PrrQ[CHA][MEG]C-NH2 199 ± 76
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evaluated by binding assays for KOR, MOR, DOR, and NOP to
ensure selectivity for KOR with selected leads evaluated for
KOR functional activity. GPCR signaling56 is a very
complicated process with multiple signaling pathways possible
that are further complicated by crosstalk. KOR predominantly
couples to Gi/0-proteins, which inhibit adenylate cyclases upon
activation of the receptor which leads to an inhibition of cAMP
production.56 Two functional readouts57 of KOR activation
were chosen and monitored for this study: a cAMP assay58 and
an ERK1/2 phosphorylation assay.59 The cAMP assay was
selected as a measure of direct KOR mediated activation of
Gi/o-proteins, and ERK1/2 assay was elected because it is
further downstream of direct KOR activation and also
encompasses signals generated by Gβ/γ subunits and β-arrestin
activation of mitogen activated protein kinases (MAPK).60
Initial Structure−Activity and Metabolic Stability
Profiling. An alanine scan of 1 resulted in analogues (2−5)
and revealed that KOR affinity (Table 1) was reduced when
residues 4−7 (RRQI) were individually replaced by alanine.
The N-terminal asparagine (N) residue was replaced by a
pyroglutamic acid (U) (→6) without affecting affinity, while an
aromatic amino acid (Y) in this position improved affinity (→
7). Truncation of peptide 1 (analogues 8−11) revealed a
minimal active sequence of RRQICC (10), with the C-terminal
vicinal disulfide moiety identified as critical for high KOR
affinity (→8, 9). Vicinal disulfide moieties are found on active
sites of enzymes,61,62 near binding site on receptors,61−63 and in
a number of toxins.64−67 In proteins, this unique eight-ring
structure prefers to adopt a type VIII turn with a distorted
trans-amide conformation.61 In small peptides, cis or trans
amide conformation is observed, with the strength of the
disulfide bond increasing in the cisoid conformation.68 The
ability to ring system flip depending on redox state makes
vicinal disulfide bonds an important class of regulatory
conformational switches.61,69 In small ring systems the vicinal
disulfide bond has exceptional redox stability as well as
structural importance.18 Alanine scan analogues of 1 revealed
that the Ile (I) positioned next to the vicinal disulfide also
contributed to high affinity binding (5). To investigate this
position further, analogues with aliphatic as well as aromatic
residues were produced (12−16); these analogues indicated
that binding affinity increased with the size of the aliphatic side
chain (V, 12 < I, 1 < L, 13 < [CHA], 14) (Table 1). Similar
results were obtained with aromatic residues, with phenyl-
alanine (F, analogue 15) and naphthylalanine (16) replace-
ments further enhancing KOR affinity (Table 1). Replacing the
Table 1. continued
compd sequence Ki ± SD (nM) ERK EC50 ± SD (nM) cAMP EC50 ± SD (nM) T1/2 plasma
58 URRQ[CHA][ACC] -NH2 12939 ± 4254
59 Bz-PrrQ[CHA][MPC]C-NH2 786 ± 389
60 Bz-PrrQ[CHA]C[MPC] -NH2 208 ± 68
61 Nz-PrrQ[CHA]CC-OH 229 ± 19 30 min
62 4Cl-Bz-PrrQ[CHA]CC-OH 795 ± 135
63 Bz-PrrQ[CHA]CC-OH 2141 ± 197
64 Bz-PrrQ[CHA]-NH2 22504 ± 3218
65 Bz-PrrN[CHA]CC-NH2 0.61 ± 0.12
66 Bz-PrrR[CHA]CC-NH2 0.23 ± 0.1 720 min
67 Bz-PrrK[CHA]CC-NH2 0.59 ± 0.12
68 Bz-PrrA[CHA]CC-NH2 0.29 ± 0.14
69 Bz-PrrL[CHA]CC-NH2 1.4 ± 0.6
70 Bz-PrrS[CHA]CC-NH2 0.42 ± 0.11
71 Bz-PrrF[CHA]CC-NH2 0.59 ± 0.07
72 Bz-PrrG[CHA]CC-NH2 0.16 ± 0.03 60 min
73 Bz-PrrD[CHA]CC-NH2 10.2 ± 2.1
74 Bz-PrrE[CHA]CC-NH2 19.4 ± 5.6
75 Bz-Prr[CHA]CC-NH2 60 ± 11.7
aKOR binding affinity (Ki), selected functional data of key analogues (Surefire-ERK and cAMP, EC50), and plasma half life (T1/2) are shown. Data
represented are the mean ± SD values from at least N = 3 experiments each performed in triplicate.
Table 2. Plasma Stability Evolution of Selected κ Agonist Peptides 23, 26, 39, 44, and 45a
compd sequence time of analysis [min] fragments detected by MS relative abundance by HPLC
23 URRQ[CHA]CC 60 URR 0.01
Q[CHA]CC 0.01
URRQ[CHA] 0.1
URRQ[CHA]CC 1
26 UrrQ[CHA]CC 120 UrrQ[CHA] 0.1
UrrQ[CHA]CC 1
39 BzPrrQ[CHA]CC 360 BzPrrQ[CHA] 0.1
BzPrrQ[CHA]CC 1
44 UrrQ[CHA][PEN]C 3600 UrrQ[CHA][PEN]C 1
45 BzPrrQ[CHA][PEN]C 3600 BzPrrQ[CHA][PEN]C 1
aFormation of peptide fragments was investigated by analytical HPLC and mass spectroscopic characterization. On the basis of the fragments
identified, the labile amide bonds were modified (23 → 26 → 39 → 44 → 45) to improve stability without adversely affecting KOR affinity (see
Table 1).
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strongly basic arginine (R) residues with histidine (H) (17, 18),
lysine (K) (19, 20), or citrulline [CIT] (21, 22) decreased
binding affinity, suggesting that arginine is optimal at this
position for KOR affinity. Combining these favored replace-
ments generated URRQ[CHA]CC (23), which had a 10-fold
improved binding affinity compared to 1 at KOR; thus 23 was
chosen as a promising early lead.
Peptides 1 and 23 survived intact for only a few minutes in
plasma and therefore were not considered suitable for further
development (Table 2 and Figure 3). From stability studies of
23 in rat plasma (Table 2), it was found that the main cleavage
site was at the vicinal Arg, as well as a minor cleavage site
between [CHA]-5 and the vicinal disulfide moiety. However,
reduction of the vicinal disulfide bond was not observed in any
of the peptides investigated, confirming its previously observed
redox stability.18 The major site of metabolic liability was
addressed by the introduction of D-Arg residues (24−26) that
maintained binding affinity to KOR but had significantly
increased plasma stability, with UrrQ[CHA]CC (26) showing a
plasma half life of 6 h (Table 1). Table 2 shows the absence of
fragments related to cleavage within the Arg region of 26,
confirming that the L- to D-Arg change directly enhanced
metabolically stability.
Design of Improved KOR Agonists. From initial analog
design, YCCRRQICC (7) had slightly improved binding
affinity compared to 1, indicating additional aromatic
participation might further improve binding affinity at KOR
as observed for dynA (1−17) and other enkephalins.44 From
this knowledge and the sequence similarity of our KOR agonist
peptides like 7 with dynA (1−8), we designed analog 26 with
an aromatic substituted N-terminus. Further analogs included
N-terminal capping using aryl substituted acetic (27−29) or
propanoic acid (30−32), bicyclic aromatic and heteroaromatic
building blocks (33−36), and substitution of the pyroglutamyl
moiety with proline and subsequent N-benzoylation (37−43)
(see Figure 2). As expected, a number of these N-terminal
analogues had enhanced affinity (Table 1). Whereas benzoyl
substitutions (27−29) appeared unable to access the aryl-
binding pocket of the receptor, the CH2 extended benzyl-
carboxyl substituents (30−32) enhanced affinity and the more
constrained bicyclic analogues (33−36) yielding further
improvements in affinity. Subnanomolar affinity analogues
(37−43) were produced by substituting the pyroglutamate
residue in 26 with the structurally related proline in
combination with N-benzoyl aromatic substitution (Table 1).
Enhancing High Affinity KOR Agonist Stability. Peptide
26 and high affinity analogues 33−43 were unstable in plasma
(Table 2 and Figure 3), with prominent cleavage evident
between the amide bond of the cyclohexylalanine [CHA]
residue and the vicinal disulfide bond. Introducing a penicill-
amine [PEN] at Cys6, adjacent to the labile amide bond,
Table 3. Opioid Receptor Selectivity Data of Selected κ Agonist Peptides (1, 6, 11, 23, 26, 39, 44, and 45) Compared to
Dynorphin A (1−17)a
fold selectivity vs KOR
compd sequence Ki ± SD (nM) MOR DOR NOP
dynorphin A (1−17) YGGFLRRIRPKLKWDNQ 0.28 ± 0.25 >60 >2000 >500
1 (1−2, 3−4) NCCRRQICC 80.4 ± 42.6 >630 >630 >630
6 UCCRRQICC 67.5 ± 6.7 >630 >630 >630
11 URRQICC 191 ± 35 >250 >250 >250
23 URRQ[CHA]CC 6.7 ± 1.1 >10000 >10000 >10000
26 UrrQ[CHA]CC 3.9 ± 1.5 >10000 >10000 >10000
39 BzPrrQ[CHA]CC 0.25 ± 0.13 >250000 >250000 >45000
44 UrrQ[CHA][PEN]C 1.3 ± 0.5 >39000 >1200 >25000
48 BzPrrQ[CHG]CC 0.48 ± 0.22 >125000 >125000 >125000
aFrom the initial conopeptide hit (1), evolved molecules (39, 48) show a clearly improved selectivity profile, while maintaining KOR affinity
equipotent to dynorphin A.
Figure 2. N-terminal aryl modifications of 26 (UrrQ[CHA]CC-NH2.
Substitution of the pyroglutamate (U) residues by aryl substituted
building blocks resulted in significantly improved KOR agonist (30 →
43). Pep = peptidyl residue with sequence HN-rrQ[CHA]CC; X =
aryl substituent. For sequence details and KOR binding see Table 1.
Figure 3. Plasma stability conorphins 6, 23, 26, 39, 44, 45, and 48 in
rat plasma at 37 °C. Shown is % remaining peptide determined by
HPLC over time.
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significantly improved plasma stability (see 44, 45 in Table 2
and Figure 4) most likely by the two protruding β-methylene
groups of PEN restricting protease access. The introduction of
penicillamine into the vicinal disulfide bond (26 → 44)
maintained binding affinity, though the benzoyl-prolyl analogue
39 lost affinity at KOR after introduction of the PEN residue
(39→ 45). This affinity shift further confirmed the importance
of the vicinal disulfide as part of the pharmacophore for this
class of peptides and suggested that this moiety may structurally
preorganize the pharmacophore to enhance KOR affinity.
To stabilize the labile amide bond, we N-methylated Cys6 of
39 (39 → 46) by site directed N-methylation via sulfonamide
formation, using a Mitsunobu reaction with methanol and final
removal of the activating sulfonamide by adapting a procedure
from Biron et al.70 However, the N-methyl analogue 46 had
reduced KOR affinity. Reduction of the amide bond in 39 via
an adaptation to the procedure of Guichard et al.,71 where the
amide carbonyl (CO) group was replaced with a CH2 group
to yield a methylene−amino (CH2−NH) linkage from the
CHA-5 residue to the Cys-6 residue 47, resulted in a 4-fold
plasma half-life improvement (t1/2 = 16 h) but reduced KOR
affinity compared to 39. The methylamino group introduction
in 47 was achieved using Fmoc-cyclohexylalanine, transfer to its
Weinreb amide, cyanoboron hydride reduction to the
respective amino acid aldehyde, and final reductive amination
on solid phase onto a H2N−CC Rink amide resin using an
adaptation to a procedure by Guichard et al.71 Further stability
improvements were achieved by replacing the CHA-5 residue
with a cyclohexylglycine [CHG] (39→ 48), and 48 maintained
KOR affinity, with an improvement in plasma stability to t1/2 =
20 h.
Vicinal Disulfide Ring Mimetics. To investigate the role
of the vicinal C-terminal cysteine moiety, we introduced a
number of eight-membered ring mimetics (Figure 4).
Replacement of cysteine by homocysteine either individually
or together yielded analogues with extended ring sizes (49, 50)
resulting in a significant loss of KOR affinity. Replacement of
the disulfide bond by a diseleno bond (35 → 52) or a sulfur-
seleno bond (26 → 53) was possible without loss of affinity,
but no metabolic stability improvement was observed. The
replacement of the disulfide bond with an amide bond (54) was
achieved via side chain to side chain cyclative amidation
between an aspartic acid and α,β-diaminopropionic residue,
yielding a cyclic product with the same ring size as the vicinal
cysteine (54); however, this analogue showed a significant loss
of KOR affinity. An increased ring size that maintained the soft
polarizable sulfur atoms within the ring system was obtained by
inserting a methylene bridge (-S-CH2-S-) to generate the
methylene dithioether peptide 55 using a solid phase
adaptation from Ueki et al.72 However, the resultant
dithiomethylen ether derivative 55 also showed reduced KOR
affinity. The ring size was also varied by incorporation of N-
thiomethylglycine building blocks instead of cysteine resulting
in a seven- (56) or nine-member (57) ring system containing
both a disulfide bond and an N-substituted amide bond. Both
analogues lost KOR affinity, and replacement of the S−S bond
in compound 56 by a CH2−CH2 in 58 almost abolished KOR
affinity. To incorporate an additional constraint into the vicinal
C-terminal moiety, 4-thioproline building blocks were used to
generate bicyclic products (59, 60) that also lost KOR affinity.
Finally, we investigated the role of the C-terminal amide.
Synthesis of the most active KOR agonists (37−39) as the acid
Figure 4. Vicinal disulfide mimetics. Modifications of C-terminal vicinal disulfide moiety and adjacent amide bonds (structure shown in square) in
peptides 44−63. Pep = peptidyl residue XrrQ[CHA] with a N-terminal modification X as shown in Table 1.
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form (61−63) produced peptides with greatly reduced affinity
for KOR.
Although we were able to replace the vicinal disulfide with a
wide variety of structural mutations, most of these analogs had
reduced affinity for KOR. This suggested that the eight-
membered vicinal cysteine ring system is a critical component
of the pharmacophore for this series of KOR receptor agonists,
perhaps through a structural preorganization or because the
disulfide-containing moiety interacts with the KOR. If the role
of the vicinal disulfide moiety were purely structural, replacing
the vicinal disulfide bond with bioisosteric groups that mimic
the vicinal disulfide moiety would be expected to have little
effect on KOR activity. Selenium has very similar physicochem-
ical properties as sulfur,73 and it has been shown that diseleno
and seleno-sulfur bridges can be used to replace disulfide
bridges without affecting structure.74 The synthesized seleno-
cysteine analogues 52 and 53 had similar KOR affinity
compared to their disulfide analogues 26−35, supporting the
importance of the vicinal disulfide moiety as a structural
contributor of the pharmacophore. This is further confirmed;
when peptide 39 is truncated and the vicinal cysteine removed,
the remaining hexapeptide 64 is completely inactive at KOR.
Role of the Gln Insert in Conorphins. From previous
chimeric peptide studies45,46 it is suggested that dynA (6−8)
(Arg6-Arg7-Ile8) contributes to the selectivity for KOR
whereas our series contains Arg-Arg-Gln-Ile. To investigate
the role of the glutamine (Gln, Q) inserted between the
arginine residues and the aliphatic isoleucine/cyclohexylalanine
residues, several analogues were produced replacing glutamine
(65−74). The majority of amino acids were well tolerated
(65−72) with the exception of aspartic and glutamic acid (73,
74), which lost significant KOR affinity (Table 1). Surprisingly,
deleting the glutamine residue from the sequence (75) also
strongly reduced binding affinity to KOR. These results
indicate that glutamine is not part of the pharmacophore but
acts as spacer for optimal presentation of the conorphin
pharmacophore. Consistent with this conclusion, replacing
glutamine with a glycine residue (72) had little effect on KOR
affinity.
Functional Assay of Developed Conorphines. The
conorphin SAR and pharmacophore development was driven
by affinity data obtained from a radioligand binding assay. To
further validate select key molecules 1, 6, 11, 23 26, 39, 44, and
48, we performed functional assays57 monitoring the efficacy of
these ligands on two key intracellular signaling pathways,
namely, cAMP58 for direct KOR activation and ERK1/259 as a
pathway further downstream of Gi/o-protein activation and
encompassing contributions from Gβ/γ-subunits and β-arrestins.
These functional assays delivered efficacy data (Table 1) that
confirmed the molecules as full agonists at KOR (intrinsic
efficacies of molecules 1, 6, 11, 23, 26, 39, 44, and 48
compared to dynA (1−17) were all in the range of 90−150%;
see Supporting Information comparing initial lead molecule 1
and advanced analogue 39 with dynA (1−17)). Interestingly,
the most potent analogues 39 and 48 had similar affinity and
efficacy (cAMP and ERK1/2) at KOR as dynA (1−17) (Table
1). Less potent analogues 1, 6, 11, 23, 26, and 44 showed some
discrepancies between binding affinity and the efficacy
measured at the two functional assays. The biased signaling
of molecules is currently of great interest in the field of
pharmacology, as it has been suggested that biased ligands
maybe able to avoid the side effects associated with some drugs
that activate all pathways of a receptor equally.75 These data
provide a basis for future detailed studies into the biased
signaling nature of some molecules, which is already of interest
for the opioid receptors as a possible mechanism to avoid side
effects.76
Selectivity Profile of Developed Conorphins. The
previously described lead optimization work was strongly
focused on KOR affinity and peptide stability optimization. To
ensure that while improving activity, selectivity for KOR was
not lost, we investigated selected key milestone molecules (1, 6,
23, 26, 39, 44, 48), where strong structural changes were made,
for their receptor selectivity. The selectivity profile of dynA (1−
17) and selected peptides, e.g., 1, 6, 23, 26, 39, 44, 48 at other
opiate receptors (Table 3) indicated that improvements in
KOR affinity paralleled improvements in KOR selectivity
relative to MOR, DOR, and NOP.
Conorphin Pharmacophore Model. The pharmacophore
of this novel series of KOR agonist peptides33 is represented
using the most potent analogue 39 in Figure 5. The
pharmacophore is defined by an aromatic N-terminal residue
Figure 5. KOR pharmacophore model for conorphins built from 39.
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[BzoP-1] where proline acts as spacer and structural constraint,
with the aromatic moiety amidating proline’s nitrogen atom.
We showed that the subsequent arginine residues (Arg2, Arg3)
are essential for high KOR affinity, with D-Arg replacements
producing potent analogues with improved plasma stability.
The glutamine residue (Gln-4) appears to act as a simple spacer
group to the adjacent position [CHA]-5, which was critical for
high affinity binding. While cyclohexylalanine [CHA] showed
the best results, other aliphatic and aromatic residues are
accepted at this position, indicating an interaction with a
hydrophobic binding pocket within KOR. The C-terminal
vicinal disulfide cysteine pair was essential in maintaining high
KOR affinity, and most alterations significantly reduced KOR
affinity. The C-terminal amide also contributes to KOR affinity,
indicating that the vicinal disulfide might play a spacer role to
influence the relative orientation of the C-terminal amide and
the rest of the pharmacophore, as well as potentially having
structurally stabilizing and/or direct interactions with the KOR
receptor. Unfortunately, NMR investigation of compound 39
showed multiple conformations in solution, making an exact
structure model unfeasible. On the basis of the SAR evidence
provided, we conclude that these KOR agonists might mimic
the interaction of dynA with the KOR. To strengthen this
conclusion, based on the obtained SAR data, a docking study of
the peptide ligand 39 to the orthosteric binding site of the KOR
was performed with AutoDock, and was confirmed against the
docking results obtained for dynA (1−8).50
Molecular Docking of 39 and dynA (1−8) to KOR. To
validate our docking simulations, dynA (1−8) was docked
(AutoDock) to a model of the KOR built from an X-ray
structure of KOR in complex with a small molecule antagonist
(JDTic).49 The obtained lowest energy binding pose was
Figure 6. Energy minimized docked pose of the KOR agonist 39 with the KOR. The key interactions are identified, with the carboxyl group of the
benzoyl residue forming a strong hydrogen bond with Asp138 positioning the aromatic benzoyl moiety to form hydrophobic interactions with
residues lining the TMIII. The guanyl-NH of Arg3 in 39 forms strong H-bond interactions with Tyr312 and Tyr320 in TMH7. Arg4 was rotated in
the opposite direction forming a salt bridge with Asp223 in TMH5 and a H-bond with Tyr219 in TM5. The amide bond between Arg4 and Gln5 of
peptide ligand 39 forms strong hydrogen bonds with Ser211 and Cys210 in ECL2 which provides a binding conformation specific to this peptide.
The hydrophobic amino acid in position 5 [CHA] leads to a gain of activity due to hydrophobic interaction with residues lining TMH7, including a
strong interaction with Tyr312. The C-terminal amide of the peptide ligand 39 and Glu209 form a characteristic H-bond interaction with the vicinal
disulfide moiety of importance for the placement of the C-terminal amide function. The vicinal disulfide moiety itself also forms strong hydrophobic
interaction with the cyclohexyl residue of 39 and weak van der Waals and hydrophobic interactions between the vicinal disulfide eight-membered
ring moiety and residues at the extracellular part of the TM3, TM4, TM5.
Table 4. Prominent Interactions of the KOR Receptor Residues with DynA (1−8) and KOR Agonist 39 Reveal a Strong Binding
Site Overlapa
KOR receptor dynA (1−8) peptide ligand 39
Asp138 (TMIII) NH2-Tyr1/Tyr1-CO-NH-Gly2 Bz-CO-
Cys210 Arg4-CO-NH-Gln3
Ser211 Arg6-CO/Arg-6-guanyl Arg4-CO-NH-Gln3
Tyr219 Arg7-guanyl Arg4-guanyl
Asp223 HO-Tyr1 Arg4-guanyl
Tyr312 Gly3-CO-NH-Phe4 Arg3-guanyl
Phe4-CO-NH-Ile5
Ile5-CO-NH-Arg6
Arg7-CO-NH-Ile8
Tyr320 Arg3-guanyl
aInteracting sites on the ligands are shown in bold.
Journal of Medicinal Chemistry Article
DOI: 10.1021/acs.jmedchem.5b00911
J. Med. Chem. 2016, 59, 2381−2395
2388
compared to the pose previously generated for dynA (1−8).50
Consistent with this docking pose, strong H-bonds are formed
between the N-terminal amine and Asp138, a hydrogen bond
was also observed between the NH of the amide bond between
Tyr1 and Gly2 of dynA (1−8) and Asp138 in the receptor, and
Gly2 and Gly3 are at the base of the orthosteric binding site. In
this pose, the CO between Gly3 and Phe4, the NH between
Phe4 and Ile5, the CO between Ile5 and Arg6, and the CO
between Arg7 and Ile8 form hydrogen bonds with Tyr312 in
TMH7, Tyr1-hydroxyl forms weak interactions with Lys227
and Asp223 in TMH5, Phe4 forms hydrophobic interactions
with residues lining the TMH3, and Asp138 in TMH3 forms a
strong hydrogen bond with the amide bond between Phe4 and
Ile5. This pose allows the two arginine to face toward TMH5
and ECL2, with Arg6 interacting with Ser211 in ECL2 and
Arg7 with Tyr219 in TMH5 via hydrogen bonds and the
terminal amide of dynA (1−8) to interact with Tyr313 in
TMH7 and Gln115 in TMH2. These interactions of dynA (1−
8) with KOR are consistent with the results50 previously
described, validating our docking studies.
By use of the same approach, the molecular docking of KOR
agonist 39 (see Figure 6) revealed a low energy docking pose
that partially overlapped the binding site with dynA (1−8) and
was consistent with our structure−activity studies (see Table
4). Similar to what was observed for dynA (1−8) is Asp138 in
TMH3 strongly involved in binding of 39. Rather than the
observed salt bridge between the N-terminal amine and Asp138
in the dynA (1−8) docking pose, we did observe that the
carboxyl group of the benzoyl residue in 39 forms a strong
hydrogen bond with Asp138 in TMH3 in the orthosteric
binding site, while the aromatic benzoyl moiety forms
hydrophobic interactions with residues lining the TMIII. The
benzoyl-prolyl residue in the orthosteric site is further stabilized
by the interaction of NH between Arg3 with Tyr312 in TMH7,
while the guanyl-NH of Arg3 in 39 formed strong H-bond
interactions with Tyr312 and Tyr320 in TMH7. The lowest
energy binding pose revealed Arg4 was rotated by 180°
compared to dynA (1−8) to form a strong salt bridge with
Asp223 in TMH5 and a H-bond with Ser211 in ECL2. These
strong Arg3 and -4 interactions are consistent with these
arginine residues being essential for high affinity binding to the
KOR. The amide bond between Arg4 and Gln5 of peptide
ligand 39 forms strong hydrogen bonds with Ser211 and
Cys210 in ECL2 which provides an ECS (extracellular surface)
binding conformation specific to this peptide. Gln5 in 39 holds
minor interactions with the receptor residues surrounding
TMII and TMIII, which explains our SAR results, that many
Gln5 amino acid substitutions are tolerated (e.g., 65−71)
without loss of activity. In contrast, acidic groups in position 5
resulted in strong activity loss (e.g., 72, 73). We speculate that
this is due to the presence of the acidic residues in the upper
half of the ECS imparting negative charge to the receptor,
thereby repelling most of the acidic peptide ligands (e.g., 72,
73, and 61−63) attempting to enter the orthosteric binding
site. The in position 6 located cyclohexyl alanine residue is
important for high KOR affinity. A change in size of the
hydrophobic side chain has resulted in gain of activity (see 12;
V < 13; L < 14; [CHA]), but also aromatic residues such as
Phe (15) or [NAL] (16) are tolerated at this position. The
observed docking model reveals hydrophobic interaction with
residues lining TMH7 (Leu309, Tyr313), including a strong
interaction with Tyr312. Furthermore, a close proximity (4.4
Figure 7. (A) The KOR agonist 39 had no effect on healthy splanchnic colonic nociceptor mechanosensitivity at any of the doses tested (P > 0.05, n
= 7). (B) However, the KOR agonist 39 caused dose-dependent inhibition of colonic nociceptors from mice with CVH (28-days post-TNBS
administration; (∗∗∗) P < 0.001 at 10 nM; (∗∗∗∗) P < 0.0001 at 100 nM and 1000 nM, n = 6; one-way ANOVA, Bonferroni post hoc). (C) Change
in mechanosensitivity induced by the KOR agonist 39 in healthy and CVH nociceptors compared to their respective baselines. The KOR agonist
caused significantly more inhibition at 10 nM ((∗∗∗∗) P < 0.0001), 100 nM ((∗∗∗∗) P < 0.0001), and 1000 nM ((∗∗∗∗) P < 0.0001) in CVH
nociceptors than healthy nociceptors (two-way ANOVA, Bonferroni post hoc). (D) This KOR agonist 39 induced inhibition of CVH nociceptors
was blocked by prior addition of the KOR antagonist Nor-BNI (100 nM; P > 0.05, n = 8), confirming the involvement of KOR activation in the
observed effect. (E) A single dose of KOR agonist 39 (100 nM) inhibited CVH colonic nociceptor mechanosensitivity ((∗∗∗∗) P < 0.0001, n = 8).
Comparison of the inhibitory effect of the KOR agonist 39 (n = 8) vs Nor-BNI plus KOR agonist 39 (n = 8) shows that the inhibitory effect of KOR
agonist 39 is blocked by the KOR antagonist.
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Å) of the disulfide bond in 39 and the cyclohexyl residue was
observed which is indicative for intramolecular hydrophobic
interaction resulting in structural constraining of 39 within the
KOR binding site. This intramolecular interaction may explain
the importance of the vicinal disulfide bond in the observed
SAR studies. A characteristic weak hydrogen bond is observed
between the C-terminal amide of the peptide ligand 39 and
Glu209 after energy minimization of the docked structure with
YASARA Web server. The activity loss for the C-terminal acid
version (61−63) of peptide agonist can again be explained by
the unfavorable repulsion with Glu209 and with the highly
acidic extracellular surface limiting access to the orthosteric site.
The vicinal disulfide moiety adjacent to the C-terminal amide is
important for the placement of the C-terminal amide function.
But the vicinal disulfide moiety itself also forms strong
intramolecular hydrophobic interaction with the cyclohexyl
residue in 39 and is not well-defined at the mouth of KOR with
weak van der Waals and hydrophobic interactions between the
vicinal disulfide eight-membered ring moiety and residues at
the extracellular part of the TMIII, TMIV, TMV, TMVI, and
TMVII. This observed intramolecular hydrophobic interaction
between the disulfide bond and cyclohexyl alanine as well as the
H-bond between the C-terminal amide and Glu209 may explain
the importance of the vicinal disulfide group for maintaining of
bioactivity and herewith the detrimental effect if replaced by
any other moiety (see 54−60) or deleted from the molecule
(→64). As a caveat of these interpretations, one should keep in
mind that the employed KOR model was based on an X-ray
structure in an antagonist bound conformation.49
Nevertheless the obtained docking pose of the peptide
agonist 39 shown in Figure 5 can explain the obtained SAR
results to a large extent and does herewith also confirm the
proposed SAR based pharmacophore model. Therefore, we
have shown that the developed KOR agonists of type 39 are
peptide mimetics of dynorphin A.
Analgesic Action of 39 in a Model of Chronic Visceral
Hypersensitivity (CVH). We have previously established that
KOR expression on colonic nociceptors is functionally up-
regulated during chronic visceral hypersensitivity (CVH)
associated with chronic abdominal pain.43 Analogue 39 was
tested for the ability to modify colonic nociceptor mechano-
sensory function in healthy and during postinflammatory
chronic visceral mechanical hypersensitivity (CVH). Com-
pound 39 was tested on the mechanosensitivity of colonic
afferents using ex vivo recordings of mice splanchnic high-
threshold afferents. These afferents respond to focal compres-
sion and have response thresholds above the physical range and
thus likely function as nociceptors. Additionally, they display
pronounced mechanical hypersensitivity and lowered activation
thresholds in models of acute and chronic visceral pain.
Nociceptor mechanosensitivity was assessed before and after
increasing doses of 39. Agonist 39 had no effect at any dose
tested on healthy nociceptor mechanosensitivity (Figure 7A).
In contrast, when recordings were performed from mice with
CVH, 39 showed dose-dependent inhibition of colonic
nociceptor mechanosensitivity (Figure 7B). Overall, 39 had a
significantly greater inhibitory effect in the CVH model (Figure
7C). On the basis of these results, it can be concluded that 39
inhibits splanchnic colonic nociceptor mechanosensitivity
during CVH but not in normal healthy colon. We also show
that the inhibitory effect of 39 is blocked by a KOR selective
antagonist (nor-BNI; norbinaltorphimine) (Figure 7D and
Figure 7E). The select inhibitory effect of KOR agonist 39 is
consistent with our previous findings using asimadoline, which
only showed efficacy in the CVH state43 and appears to inhibit
nociception via activation of KORs expressed on the peripheral
endings of colonic nociceptors, suggesting a peripherally
restricted KOR agonist might be useful treatment for a variety
of visceral pain conditions including irritable bowel syndrome.
Notably, in human patients with IBS, asimadoline has been
shown to significantly decrease pain perception in response to
colonic distension.77 Interestingly, in a phase IIb study
asimadoline’s efficacy against symptoms of IBS was greatest
in D-IBS patients, with at least moderate pain at baseline.78
■ CONCLUSION
A first of a kind class of KOR agonists were discovered and
developed based on the initial nine-residue hit from a
conopeptide venom library. Through systematic structure−
activity relationship (SAR) elaboration, conorphin-T led to the
development of an initial pharmacophore containing a critical
C-terminal vicinal disulfide that allowed for the rational design
of analogues with highly improved properties. The initial lead 1,
which had a short plasma half-life (t1/2 = 15 min) and
nanomolar affinity and micromolar efficacy (Ki = 80.4 nM, EC50
= 9.848 μM), was systematically modified to yield eight-residue
peptides (e.g., 39) with subnanomolar affinity, efficacy (Ki =
0.25 nM, EC50 = 0.36 nM) and improved plasma stability (t1/2
= 240 min). Using in vitro metabolic studies, we were able to
identify cleavage sites that were modified to produce analogues
with significantly improved plasma stability (>24 h). These
stable, potent, and selective KOR agonists contained a
pharmacophore resembling that of dynorphin A, with modeling
studies revealing dynA (1−8) and 39 to have overlapping
binding sites on KOR. The KOR agonist 39 inhibited
splanchnic colonic nociceptors during CVH but not in the
normal healthy colon and represents promising a lead for the
development of IBS treatments.
■ EXPERIMENTAL SECTION
Materials. Protected Fmoc-amino acid derivatives were purchased
from Novabiochem or Auspep P/L. The following side chain
protected amino acids were used: Cys(Acm), Cys(Trt), His(Trt),
Hyp(tBu), Tyr(tBu), Lys(Boc), Trp(Boc), Arg(Pbf), Asn(Trt),
Asp(OtBu), Glu(OtBu), Gln(Trt), Ser(tBu), Thr(tBu), Tyr(tBu).
All other Fmoc amino acids were unprotected. Unusual Fmoc amino
acids [HTY], [ORN], [HLY], [CIT], and [BHK] were used with
following side chain protections: -OH as -OtBu, -NH2 as -NH(Boc),
-COOH as -COO(tBu), and -SH as -S(Trt). All other unusual Fmoc
amino acids were used unprotected. Unusual amino acids were
sourced from Novabiochem, Auspep, CSPS-Pharmaceuticals, or
NeoMPS. L-α-Hydroxyisovaleric acid was used unprotected. Dime-
thylformamide (DMF), dichloromethane (DCM), diisopropylethyl-
amine (DIEA), trifluoroacetic acid (TFA) were supplied by Auspep P/
L (Melbourne, Australia) as peptide synthesis grade. 2-(1H-
Benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate
(HBTU), triisopropylsilane (TIPS), Tris-HCl, MgCl2, bovine serum
albumin (BSA), HEPES, EDTA, glycerol, HPLC grade acetonitrile,
and methanol were supplied by Sigma-Aldrich (St. Louis, MO, USA).
The resin used was Fmoc-Rink resin (0.65 mmol/g) supplied by
Auspep P/L, and Wang resin (0.81 mmol/g) was supplied by
Novabiochem. Ethane dithiol (EDT) was supplied by Merck, 3H-
U69,593, 3H-naltrindole, 3H-diprenorphine, 3H-nociceptin, DOR,
MOR, NOP membranes, FlashBlue GPCR scintillation beads,
Alphascreen SureFire phospho-ERK1/2 kit were purchased from
PerkinElmer (Waltham, MA, USA). Trans-IT CHO transfection kit
was purchased from Mirus (Madison, WI, USA). Ham’s F-12 media,
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FBS, trypsin-EDTA, and PBS were purchased from Life Technologies
(Carlsbad, USA).
Synthetic Strategy. Peptide amides were synthesized on an
Advanced ChemTech (ACT-396) automated peptide synthesizer
using Rink amide resin (0.05 mmol). Peptide acids were synthesized
on Wang resin loaded with the C-terminal Fmoc-Cys(Trt)-OH using
MSNT/1-methylimidazole activation (4 equiv excess). Continued
assembly for the peptide acids as well as the complete assembly of
peptide amides was performed using HBTU in situ activation
protocols79 to couple the Fmoc-protected amino acid or unprotected
acids to the resin (4 equiv excess). After chain assembly and, if
required, final Fmoc deprotection, the reaction block was transferred
onto an ACT-LABTECH shaker and peptides were cleaved from the
resin at room temperature (rt) in TFA:H2O/TIPS/EDT
(87.5:5:5:2.5) for 3 h. Cold diethyl ether (30 mL) was then added
to the filtered cleavage mixture and the peptide precipitated. The
precipitate was collected by centrifugation and subsequently washed
with further cold diethyl ether to remove scavengers. The final product
was dissolved in 50% aqueous acetonitrile and lyophilized to yield a
white solid. The crude, reduced peptide was examined by reversed-
phase HPLC for purity and the correct molecular weight confirmed by
electrospray mass spectrometry (ESMS).
Synthesis of N-Methylcysteine Containing Peptide 46.
Peptide 46 was assembled using the above standard Fmoc protocol
(0.1 mmol Rink amide resin) with the following exception; after
coupling of the second cysteine to the resin and Fmoc deprotection,
N-methylation was performed on resin.70 An o-nitrobenzoylsulfona-
mide is introduced using 66 mg of o-nitrobenzenesulfonyl chloride and
66 μL of 2,4,6-collidine in 1 mL of dichloromethane (18 h, 25 °C).
After washing multiple times with dichloromethane and dry
tetrahydrofuran the acidified sulfonamide N-H was methylated with
methanol (20 μL) at rt for 18 h in 2 mL of THF using 131 mg of
triphenylphosphine and 300 μL of diisopropyl azodicarboxylate. After
washing with THF and DCM the sulfon group was removed with 100
μL of DBU and 100 μL of 2-thioethanol in 1 mL of DCM. After
washing of the resin with DCM and DMF the next amino acid was
coupled using a double coupling performed with HBTU activation.
Peptide 46 was then further assembled using the above-described
standard synthesis procedure followed by cleavage and oxidation.
Synthesis of Reduced Amide Bond Peptide 47. Peptide 47
was assembled using the above standard Fmoc protocol on a Rink
amide resin (0.4 mmol) coupling the first two cysteines and
deprotecting the N-terminal Fmoc-protecting group. The reduced
amide bond was formed by reductive amidation employing initial
immin formation for 1 h with Fmoc-cycloheylalaninealdehyde (1.8
mmol) in NMP (10 mL) containing 1% acetic acid. This step was
followed by immin reduction for 48 h using Na(CN)BH3 (20 mmol)
in NMP containing 1% acetic acid. The resin was washed multiple
times with DMF (1% HOAc), MeOH, DCM, and DMF, and the
synthesis was continued using standard Fmoc protocol. The Fmoc-
cyclohexylalaninealdehyde71 was synthesized from Fmoc-cyclohexyla-
lanine (3.53 mmol) and coupling of N,O-dimethylhydroxylamine
hydrochloride (3.6 mmol) in DCM using BOP (3.53 mmol)/DIEA
(10 mmol) activation to form the amino acid Weinreb amide. After
dilution with 200 mL of DCM the solution was extracted with
solutions of NaHCO3, HCl, NaHCO3, and water. The organic phase
was dried with MgSO4 and the solvent was evaporated to deliver 1.3 g
(85% yield) of crude Fmoc-cyclohexylalanine Weinreb amide. The
Weinreb amide (2.97 mmol) was dissolved in 25 mL of dry THF and
cooled to −20 °C. LiAlH4 (3.6 mmol) was added in portions, and the
mixture was stirred until 0 °C was reached. This temperature was
maintained for a further hour. For workup, 100 mg of citric acid and
ice was slowly added to the reaction mixture. After extraction with
DCM and drying of the organic phase with MgSO4 the solvent was
removed to deliver 760 mg (2 mmol, 68% yield) of crude Fmoc-
cyclohexylaldehyde as confirmed by LC−MS and was used without
further purification in reductive amidation described above.
Synthesis of Side Chain to Side Chain Amidated Peptide 54.
Peptide 54 was assembled under standard conditions as described
above. After HPLC purification of the linear peptide Bz-PrrQD[DAP],
side chain to side chain cyclization was obtained by dissolving 27 mg
of starting peptide in 30 mL of DMF and adding 1 mL of a 0.05 M
BOP solution in DMF and 1 mL of DIEA. Reaction monitoring
employing HPLC−MS was indicating completion of cyclization within
1 h. The reaction solution was diluted with 200 mL of water (0.05%
TFA) and loaded onto a C18 HPLC column for immediate
purification.
Synthesis of Methylene Dithioether Peptide 55. On Rink
amide resin (50 mg) the C-terminal dual cysteine sequence was
assembled using standard HBTU activation. The cysteine building
blocks used were side chain S-protected with the acid labile p-
methoxytrityl group. After Fmoc deprotection the CC-Rink resin was
S-deprotected using 2% TFA/4% TIPS in DCM (6 × 2 min). The
resin was then treated at 20 °C for 18 h, with 2.5 g of TBAF hydrate in
3 mL of DCM.72 After washing with DCM and DMF the synthesis was
continued using standard Fmoc protocol and workup.
Random Disulfide Bond Formation. Pure, reduced peptides
containing pairs of sulfhydryl or selenohydryl groups (1 mg/mL) were
oxidized by stirring at rt in 30% DMSO/5% HOAc for 16 h. The
solutions were subsequently diluted to a DMSO concentration of <5%,
prior to RP-HPLC purification and lyophilization.
Selective Disulfide Bond Formation.15 Selectively folded
peptide isomers of 1 were assembled on Rink (amide) resin. For
each of the different isomers one pair of cysteine residues was
incorporated into the sequence, using Cys(Trt) protection while the
other Cys pair used the orthogonal protection of Cys(Acm). After
cleavage and purification of the reduced peptide the first disulfide bond
was formed using the standard 30% DMSO/0.1 M NH4OAc buffer
(pH 6) method described above.
The formation of the second disulfide bond was performed by
dissolving the purified, singly oxidized di(Acm) peptide at a
concentration of 1 mM in 80% acetic acid/water. Iodine (10 equiv)
dissolved in a small volume of ethyl acetate was added and the mixture
stirred at rt. The progress of the Acm-deprotection and subsequent
disulfide bond formation was monitored by direct injection ESMS at
regular intervals until completion (∼30−90 min). The reaction was
then quenched by addition of ascorbic acid solution (10 mg/mL)
resulting in a decolorization of the solution. After dilution with 5 times
the volume of water and adjusting to pH 3, the fully oxidized peptide
was loaded onto a RP-HPLC column and purified as described below.
HPLC Analysis and Purification. Analytical HPLC runs were
performed using a Shimadzu HPLC system LC10A with a dual
wavelength UV detector set at 214 and 254 nm. A reversed-phase C-18
column (Zorbax 300-SB C-18; 4.6 mm × 50 mm) with a flow rate of 2
mL/min was used. Gradient elution was performed with the following
buffer systems: A, 0.05% TFA in water and B, 0.043% TFA in 90%
acetonitrile in water, from 0% B to 80% B in 20 min. The crude
peptides were purified by semipreparative HPLC on a Shimadzu
HPLC system LC8A associated with a reversed-phase C-18 column
(Vydac C-18, 25 cm × 10 mm) running at a flow rate of 5 mL/min
with a 1% gradient of 0% B to 40% B. The purity of the final product
was evaluated by analytical HPLC (Zorbax 300SB C-18: 4.6 mm ×
100 mm) with a flow rate of 1 mL/min and a 1.5% gradient of B (0−
45%). The synthesized peptides were all confirmed with >95% purity.
Electrospray Mass Spectrometry (ESMS). Electrospray mass
spectra were collected inline during analytical HPLC runs on an
Applied Biosystems API-150 spectrometer operating in the positive
ion mode with an OR of 20, Rng of 220, and Turbospray of 350
degrees. Masses between 300 and 2200 amu were detected (step 0.2
amu, dwell 0.3 ms).
Plasma Stability Evaluation of Peptides.18 Stability experi-
ments were performed in triplicate with −80 °C stored Wistar rat
plasma. After defrosting at room temperature the plasma was kept on
ice. Solids were removed by centrifugation. Peptides were dissolved as
a 1 mg/mL solution in sterile PBS buffer (pH 7.4). Of these peptide
solutions, an amount of 50 μL was transferred into Eppendorf tubes
and 50 μL of the rat plasma supernatant was added. After mixing, the
samples were incubated at 37 °C. The initial sample and samples after
1 h, 2 h, 3 h, 4 h, 6 h, and 24 h were quenched with 50 μL of
acetonitrile and 400 μL of 2% TFA/water. The quenched samples
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were vortexed and analyzed by HPLC on a Hypersil Gold analytical
column (2.1 mm × 100 mm, 3 nm) using a 5−45% B with a gradient
of 2%/min and 0.3 mL flow. Peptide peak areas were integrated and
the percent peptide left, compared to the initial, was graphed against
the time. Mass spectroscopic evaluation was run in parallel to clearly
identify observed fragments.
Peptide Concentration Assessment. Peptide concentration,
used in in vitro screening, were calculated based on peak area detected
at 214 nm by HPLC. Peak area was calibrated using a peptide standard
with known peptide content established by amino acid analysis.
Molecular extinction coefficients were calculated for the standard and
the peptide of interest applying increments established by Buck et al.80
By use of the Lambert−Beer law, the peptide concentration is
calculated based on absorptions of standard and sample using
calculated extinction coefficients.
Cell Culture, Transfection, and Membrane Preparation.
CHO-KI cells were cultured in Ham’s F12, 10% FBS at 37 °C and
5% CO2. Transient transfections were performed 24 h after seeding
cells at 6 × 106 cells in a 150 mm plates using Trans-IT CHO
transfection reagent per manufacturer’s instructions (Mirus). Briefly,
the method involved combining Trans-IT CHO reagent (72 μL) in
serum-free Ham’s F-12 media incubated for 5 min at room
temperature. Following the addition of KOR receptor plasmid (24
μg), this mixture was incubated for 10 min at room temperature. CHO
Mojo reagent (16 μL) was added to the mixture and incubated for 15
min at room temperature prior to the addition to the cells.
For KOR membrane preparations the transfected cells were
harvested after 24 h by the following method. Confluent 150 mm
plates were washed with PBS, harvested by scraping into ice-cold
harvest buffer (50 mM Tris-HCl, pH 7.4, 5 mM MgCl2), followed by
homogenization with a Polytron homogenizer for 3 min on ice, then
centrifugation at 100g for 5 min at 4 °C. Supernatants were recovered
and centrifuged at 22 000g for 1 h at 4 °C. Membrane pellets were
resuspended in 0.5 mL of ice-cold harvest buffer containing 10%
glycerol and aliquots stored at −80 °C until use. The protein
concentration of the membrane preparations was determined by the
Bradford method.81
Receptor Binding Studies. Receptor binding assays were
performed using FlashBlue GPCR scintillation beads using a
previously described method.82 Briefly, FlashBlue GPCR SPA binding
assays were performed in 96-well white polystyrene plates with clear
flat bottoms (Corning). Radioligands KOR 3H-U69,593 [(5a,7a,8b)-
(−)-N-methyl-[7-(1-pyrrolidinyl)-1-oxaspiro[4,5]dec-8-yl]benzene-
acetamide] (1 nM), DOR 3H-naltrindole (0.4 nM), MOR 3H-
diprenorphine (0.2 nM), NOP 3H-nociceptin (0.26 nM)) were added
to each membrane preparation, followed by the addition of various
concentrations of competing ligands (1 pM to 10 μM) in a total
volume of 80 μL containing assay buffer A, B, or C (buffer A, B, 50
mM Tris-HCl, pH 7.4, 5 mM MgCl2, and either 0.1% (A) or 0.5% (B)
bovine serum albumin (BSA); or buffer C, 50 mM HEPES, pH 7.4, 1
mM EDTA, 10 mM MgCl2, and 0.5% BSA) (KOR and DOR assays,
buffer A; MOR assay, buffer B; NOP assay, buffer C). The final
reaction volume per well comprised 20 μL of compound/buffer, 20 μL
of FlashBlue GPCR beads (KOR, DOR, and MOR, 100 μg; NOP, 200
μg), 20 μL of membrane (∼2 μg), and the assay was initiated by the
addition of 20 μL of radioligand. The plate was then sealed with
TopSeal-A sealing film and incubated with shaking for 1 h at room
temperature. Radioligand binding was then assessed for 30 s/well on a
1450 Microbeta scintillation counter (PerkinElmer). Nonspecific
binding was determined in the presence of 10 μM Dynorphin A.
Data were analyzed using Prism 6 software (GraphPad Software, San
Diego, CA, USA) with curves generated using sigmoidal dose−
response analysis.
ERK1/2 Phosphorylation Assay. Alphascreen SureFire phospho-
ERK1/2 assay was performed according to the manufacturer’s
instructions (PerkinElmer). Briefly, cells were harvested 24 h after
transfection with 0.05% trypsin−EDTA in phosphate buffered saline
(PBS) and transferred to 96-well tissue culture plates at 50 000 cells/
well and allowed to settle for 24 h. The following day cells were serum
starved in Ham’s F-12 media for 12 h at 37 °C and 5% CO2. Ligands
were prepared in serum-free medium and then incubated at room
temperature for 10 min with cells. Medium was then removed, and
cells were lysed with lysis buffer for 10 min on a shaker. Then 4 μL of
lysate was transferred to a white 96-well half area plate (Corning) and
incubated in the presence of 7 μL of reaction mix. The plate was sealed
with TopSeal-A, transferred to plate shaker for 2 min, then incubated
for 2 h at 37 °C. Assay was than measured on an Envision plate reader
(PerkinElmer). Data were analyzed using Prism 6 software (GraphPad
Software, San Diego, CA, USA) with curves generated using sigmoidal
dose−response analysis.
Inhibition of cAMP Production Assay. The inhibition of cAMP
production following activation of KOR was measured using the
LANCE cAMP assay kit as per manufacturer’s instructions
(PerkinElmer). Briefly cells were harvested 24 h post-transfection
and added to a 96-well white half area plate (Corning) at a final
concentration of 3000 cells/well in stimulation buffer (HBSS, 0.1%
BSA, 0.5 mM IBMX, 5 mM HEPES, pH 7.4) in a volume of 5 μL. To
this 2.5 μL of forskolin (1 μM final concentration) in stimulation
buffer was added, followed by 2.5 μL of ligand/stimulation buffer. The
plate was then incubated for 30 min at rt. Following incubation, 5 μL
of Eu-cAMP tracer solution and 5 μL of anti-cAMP reagent were
added and the plate was sealed with TopSeal-A (PerkinElmer) and left
to incubate at rt for 1 h. Following incubation, TopSeal-A was
removed and plate was read in an Envision plate reader (PerkinElmer).
Data were analyzed using Prism 6 software (GraphPad Software, San
Diego, CA, USA) with curves generated using sigmoidal dose−
response analysis.
Molecular Docking. Docking of the peptide ligand to the
orthosteric binding site of KOR was performed with AutoDock. The
receptor was checked for parameters like polar hydrogens, assignment
of partial atomic Kollman charges, and solvation parameters.
Lamarckian genetic algorithm (LGA) implemented in AutoDock
tools (ADT) was used for conformational sampling of ligands. In
AutoDock, the grid maps were prepared using the AutoGrid utility
with 54 × 52 × 48 points, which is sufficiently large to accommodate
all active site residues and grid spacing set to 1.0 Å. Docking
parameters were kept as per following: number of individuals in the
population, 150; maximum number of energy evaluations, 2 500 000;
maximum number of generations, 2700; number of GA runs, 20.
Chronic Visceral Hypersensitivity (CVH) Model and Colonic
Primary Afferent Recording.Male C57BL/6 mice aged 17 weeks of
age and weighing between 28 and 32 g were used for colonic
nociceptor studies. Intracolonic trinitrobenzenesulfonic acid (TNBS;
130 μL/mL in 30% ethanol, 0.1 mL bolus) was administered as
described previously.43,83,84 TNBS-treated mice were allowed to
recover for 28 days, at which stage inflammation had resolved and
chronic colonic afferent mechanical hypersensitivity was evident.43,85,86
These mice are termed chronic visceral hypersensitivity (CVH)
mice.43,83,84 In vitro single-unit extracellular recordings of action
potential discharge were made from splanchnic colonic afferents from
C57BL/6 healthy or CVH mice using standard protocols.43,83,84,87
Baseline mechanosensitivity was determined in response to application
of a 2 g Von Frey hair probe to the afferent receptive field for 3 s. This
process was repeated 3−4 times, separated each time by 10 s.
Mechanosensitivity was then retested after application of KOR agonist,
respectively. The KOR agonist was applied to the mucosal surface of
the colon for a period of 5 min at each concentration via a small metal
ring placed over the receptive field of interest. In some instances data
are presented as “change from baseline”. This is calculated by
determining the change in mechanosensitivity of individual afferents
between the normal “baseline” response in healthy or CVH conditions
compared to the respective mechanical responses following drug or
peptide addition. In the respective study this difference is then
averaged across all afferents to obtain a final mean ± SEM of “change
in response from baseline”. Data are presented as spikes/s and are
expressed as mean ± SEM. Data were analyzed using Prism 6 software
(GraphPad Software, San Diego, CA, USA), and statistical analysis
resulting in data output in Figure 7A,B,D was performed using one-
way ANOVA followed by Bonferroni’s post hoc test. Data outputs
shown in Figure 7C were statistically analyzed using two-way ANOVA
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followed by Holm−Sidak’s post hoc test. Data outputs shown in
Figure 7E (CVH baseline Vs KOR agonist 39 and also CVH baseline
Vs NorBNI + KOR agonist 39) were analyzed using a paired t test.
Differences between specific drug concentrations and baseline
responses were considered significant at (∗) P < 0.05, (∗∗) P <
0.01, (∗∗∗) P < 0.001, or (∗∗∗∗) P < 0.0001. n indicates the number
of individual nociceptors. Experiments involving animals were
approved by the Animal Ethics Committees of The University of
Adelaide and the South Australian Health and Medical Research
Institute (SAHMRI).
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■ ABBREVIATIONS USED
KOR, κ opioid receptor; MOR, μ opioid receptor; DOR, δ
opioid receptor; NOP, nociceptin/orphanin FQ receptor; U, L-
pyroglutamic acid; [ACC], (3S)-3-amino-1-carboxymethyl-
caprolactam; [NAL], L-1-naphthylalanine; [CHA], L-cyclo-
hexylalanine; [CHG], L-cyclohexylglycine; [DAP], L-β-amino-
alanine; [CIT], L-citrulline; [NMC], N-methyl-L-cysteine;
[TIC], 1,2,3,4-L-tetrahydroisoquinoline-3-carboxylic acid;
[HCY], L-homocysteine; [PEN], L-penicillamine; [ANC], 3-
aminonaphthalene-2-carboxylic acid; [QIN], 3-quinolinecar-
boxylic acid; [TIQ], L-tetrahydroisoquinoline-1-carboxylic
acid; [SEC], L-selenocysteine; [MEG], N-mercaptoethyl-
glycine; [MPC], (2S,4S)-4-mercaptoproline; 4-Cl-Bz, 4-chlor-
obenzyl; -CH2-NH, reduced amide bond; HBTU, N,N,N′,N′-
tetramethyl-O-(1H-benzotriazol-1-yl)uranium hexafluorophos-
phate); MSNT, 1-(2-mesitylensulfonyl)-3-nitro-1H-1,2,4-tria-
zole; EDT, ethanedithiol; TIPS, triisopropylsilane; TFA,
trifluoroacetic acid; DCC, N,N′-dicyclohexylcarbodiimide;
NEM, N-ethylmorpholine; DMAP, 4-dimethylaminopyridine;
DMSO, dimethylsulfoxide; Acm, acetamidomethyl; RP-HPLC,
reversed-phase high-performance liquid chromatography; LC−
MS, liquid chromatography coupled mass spectrometry; NMR,
nuclear magnetic resonance; NOESY, nuclear Overhauser
enhancement spectroscopy; GPCR, G-protein-coupled recep-
tor; CHO, Chinese hamster ovary; TNBS, trinitrobenzenesul-
fonic acid; ERK, extracellular signal-regulated kinase
Carboxylic Acid Capping Groups
Bz, benzyl; Nz, naphthyl-2-carboxyl; Bnz, benzoyl
■ ADDITIONAL NOTE
Natural occurring amino acids are abbreviated to standard
single or three letter codes: capital letters represent L-amino
acids, and lower case letters represent D-amino acids. Unnatural
amino acids are indicated using a three letter code in square
brackets. Aromatic substitution is indicated by ring position
number and nature of substituent.
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